Novartis: Kisqali gets positive EU opinion for breast cancer
(CercleFinance.com) - Novartis' Kisqali has received a positive opinion from European health authorities for an expanded indication in the treatment of advanced breast cancer.
More precisely, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended Kisqali for the treatment of women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer in combination with fulvestrant as initial endocrine-based therapy and in women who have received prior endocrine therapy.
The EMA also recommended approval of Kisqali, in combination with endocrine therapy and a luteinising hormone-release hormone agonist for pre- and peri-menopausal women, Novartis said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.